[go: up one dir, main page]

WO2010116088A3 - Dérivés de quinazolinedione, leur préparation et leurs diverses applications thérapeutiques - Google Patents

Dérivés de quinazolinedione, leur préparation et leurs diverses applications thérapeutiques Download PDF

Info

Publication number
WO2010116088A3
WO2010116088A3 PCT/FR2010/050664 FR2010050664W WO2010116088A3 WO 2010116088 A3 WO2010116088 A3 WO 2010116088A3 FR 2010050664 W FR2010050664 W FR 2010050664W WO 2010116088 A3 WO2010116088 A3 WO 2010116088A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
therapeutic uses
preparation
various therapeutic
quinazolinedione derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2010/050664
Other languages
English (en)
Other versions
WO2010116088A2 (fr
Inventor
Annie Clauss
Christophe Glaess
Gilbert Marciniak
Jean-François Nave
Bertrand Vivet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41226702&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2010116088(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to CN201080025349.0A priority Critical patent/CN102459244B/zh
Priority to BRPI1014904A priority patent/BRPI1014904A2/pt
Priority to EP10723214A priority patent/EP2417130A2/fr
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Priority to MA34323A priority patent/MA33255B1/fr
Priority to CA2758233A priority patent/CA2758233A1/fr
Priority to AU2010233594A priority patent/AU2010233594B2/en
Priority to MX2011010639A priority patent/MX2011010639A/es
Priority to SG2011073442A priority patent/SG175130A1/en
Priority to NZ595768A priority patent/NZ595768A/xx
Priority to JP2012504055A priority patent/JP5564101B2/ja
Priority to EA201171228A priority patent/EA021765B1/ru
Publication of WO2010116088A2 publication Critical patent/WO2010116088A2/fr
Publication of WO2010116088A3 publication Critical patent/WO2010116088A3/fr
Priority to IL215609A priority patent/IL215609A0/en
Priority to US13/268,164 priority patent/US8722659B2/en
Priority to ZA2011/07363A priority patent/ZA201107363B/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Anesthesiology (AREA)

Abstract

L'invention a pour objet des dérivés de quinazolinedione de formule (I) avec A un atome de soufre ou d'oxygène ou un groupe sulfoxyde ou sulfone, leurs procédés d'obtention et leurs applications thérapeutiques tels que le cancer le diabète, les maladies musculaires, osseuses, cardiovasculaires, du système nerveux central, du système nerveux périphérique entre autres.
PCT/FR2010/050664 2009-04-09 2010-04-07 Dérivés de quinazolinedione, leur préparation et leurs diverses applications thérapeutiques Ceased WO2010116088A2 (fr)

Priority Applications (14)

Application Number Priority Date Filing Date Title
EA201171228A EA021765B1 (ru) 2009-04-09 2010-04-07 Производные хиназолиндиона, их получение и их различные терапевтические применения
SG2011073442A SG175130A1 (en) 2009-04-09 2010-04-07 Quinazolinedione derivatives, preparation thereof and various therapeutic uses thereof
EP10723214A EP2417130A2 (fr) 2009-04-09 2010-04-07 Dérivés de quinazolinedione, leur préparation et leurs diverses applications thérapeutiques
JP2012504055A JP5564101B2 (ja) 2009-04-09 2010-04-07 キナゾリンジオン誘導体、その調製およびその様々な治療上の使用
MA34323A MA33255B1 (fr) 2009-04-09 2010-04-07 Derives de quinazolinedione, leur preparation et leurs diverses applications therapeutiques
CA2758233A CA2758233A1 (fr) 2009-04-09 2010-04-07 Derives de quinazolinedione, leur preparation et leurs diverses applications therapeutiques
AU2010233594A AU2010233594B2 (en) 2009-04-09 2010-04-07 Quinazolinedione derivatives, preparation thereof and various therapeutic uses thereof
MX2011010639A MX2011010639A (es) 2009-04-09 2010-04-07 Derivados de quinazolinadiona, su preparacion y sus diversas aplicaciones terapeuticas.
NZ595768A NZ595768A (en) 2009-04-09 2010-04-07 Quinazolinedione derivatives, preparation thereof and various therapeutic uses thereof
CN201080025349.0A CN102459244B (zh) 2009-04-09 2010-04-07 喹唑啉二酮衍生物、其制备及其多种治疗用途
BRPI1014904A BRPI1014904A2 (pt) 2009-04-09 2010-04-07 derivados de quinazolinadiona, preparação dos mesmos e vários usos terapêuticos dos mesmos.
IL215609A IL215609A0 (en) 2009-04-09 2011-10-06 Quinazolinedione derivatives, preparation thereof and various therapeutic uses thereof
US13/268,164 US8722659B2 (en) 2009-04-09 2011-10-07 Quinazolinedione derivatives, preparation thereof and various therapeutic uses thereof
ZA2011/07363A ZA201107363B (en) 2009-04-09 2011-10-07 Quinazolinedione derivatives,preparation thereof and various therapeutic uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0901760A FR2944282B1 (fr) 2009-04-09 2009-04-09 Derives de quinazolinedione, leur preparation et leurs diverses applications therapeutiques
FR0901760 2009-04-09

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/268,164 Continuation US8722659B2 (en) 2009-04-09 2011-10-07 Quinazolinedione derivatives, preparation thereof and various therapeutic uses thereof

Publications (2)

Publication Number Publication Date
WO2010116088A2 WO2010116088A2 (fr) 2010-10-14
WO2010116088A3 true WO2010116088A3 (fr) 2010-12-16

Family

ID=41226702

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2010/050664 Ceased WO2010116088A2 (fr) 2009-04-09 2010-04-07 Dérivés de quinazolinedione, leur préparation et leurs diverses applications thérapeutiques

Country Status (22)

Country Link
US (1) US8722659B2 (fr)
EP (1) EP2417130A2 (fr)
JP (1) JP5564101B2 (fr)
KR (1) KR20120028872A (fr)
CN (1) CN102459244B (fr)
AR (1) AR076233A1 (fr)
AU (1) AU2010233594B2 (fr)
BR (1) BRPI1014904A2 (fr)
CA (1) CA2758233A1 (fr)
CL (1) CL2011002522A1 (fr)
CO (1) CO6440583A2 (fr)
EA (1) EA021765B1 (fr)
FR (1) FR2944282B1 (fr)
IL (1) IL215609A0 (fr)
MA (1) MA33255B1 (fr)
MX (1) MX2011010639A (fr)
NZ (1) NZ595768A (fr)
SG (2) SG175130A1 (fr)
TW (1) TW201040148A (fr)
UY (1) UY32556A (fr)
WO (1) WO2010116088A2 (fr)
ZA (1) ZA201107363B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130124333A (ko) * 2010-11-08 2013-11-13 오메로스 코포레이션 Pde7 억제제를 사용한 중독 및 충동-조절 장애의 치료
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
SI2846805T1 (sl) * 2012-05-07 2019-04-30 Omeros Corporation Zdravljenje zasvojenosti in motenj v obvladovanju impulzov z uporabo inhibitorjev PDE7
ITMI20130646A1 (it) * 2013-04-19 2014-10-20 Univ Bologna Alma Mater Composti chinazolindionici con attività inibente sulle sirtuine
CN106146413B (zh) * 2015-04-03 2019-01-18 中南大学 2,4-(1h,3h)-喹唑啉二酮衍生物及其合成方法和用途
GB201517217D0 (en) * 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
GB201517216D0 (en) * 2015-09-29 2015-11-11 Cancer Res Technology Ltd And Astex Therapeutics Ltd Pharmaceutical compounds
WO2024038090A1 (fr) 2022-08-18 2024-02-22 Mitodicure Gmbh Utilisation de composés de benzofurane et de benzoxazole substitués pour le traitement et la prévention de maladies associées à la fatigue chronique, à l'épuisement et/ou à l'intolérance à l'effort

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0638567A1 (fr) * 1993-02-18 1995-02-15 Kyowa Hakko Kogyo Kabushiki Kaisha Inhibiteur de l'incorporation d'adenosine
WO1999054284A1 (fr) * 1998-04-20 1999-10-28 Fujisawa Pharmaceutical Co., Ltd. Derives d'acide anthrenilique utilises comme inhibiteurs de cgmp-phosphodiesterase
WO2001044228A2 (fr) * 1999-12-14 2001-06-21 Sanofi-Synthelabo Derives de quinazolinedione et phtalimide, leurs preparations et leurs applications en therapeutique
WO2008133155A1 (fr) * 2007-04-19 2008-11-06 Astellas Pharma Inc. Composé hétérocyclique bicyclique
WO2009077680A1 (fr) * 2007-10-03 2009-06-25 Sanofi-Aventis Dérivés de quinazolinedione, leur préparation et leurs applications thérapeutiques

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3879393A (en) 1973-06-18 1975-04-22 Miles Lab Derivatives of 1,3-disubstituted 2,4(1h,3h)-quinazolinediones
EP0040793B1 (fr) 1980-05-22 1985-08-28 Masayuki Ishikawa Dérivés de la quinazolindione, procédé pour leur préparation et leur utilisation pharmaceutique
US5264437A (en) 1992-03-20 1993-11-23 Syntex (U.S.A.) Inc. Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones
WO2006092692A1 (fr) 2005-03-01 2006-09-08 Pfizer Limited Utilisation d'associations d’inhibiteurs de pde7 et de ligands alpha-2-delta pour le traitement de la douleur neuropathique
EP1855686A1 (fr) 2005-03-01 2007-11-21 Pfizer Limited Utilisation des inhibiteurs de pde7 pour le traitement de la douleur neuropathique
US7846664B2 (en) 2005-12-07 2010-12-07 The Regents Of The University Of California Diagnosis and treatment of chronic lymphocytic leukemia (CLL)
CN104758291B (zh) 2007-03-27 2020-03-03 奥默罗斯公司 用于治疗运动障碍的pde7抑制剂的用途
FR2944206B1 (fr) * 2009-04-09 2012-12-28 Sanofi Aventis Applications therapeutiques dans le domaine cardiovasculaire de derives de quinazolinedione

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0638567A1 (fr) * 1993-02-18 1995-02-15 Kyowa Hakko Kogyo Kabushiki Kaisha Inhibiteur de l'incorporation d'adenosine
WO1999054284A1 (fr) * 1998-04-20 1999-10-28 Fujisawa Pharmaceutical Co., Ltd. Derives d'acide anthrenilique utilises comme inhibiteurs de cgmp-phosphodiesterase
WO2001044228A2 (fr) * 1999-12-14 2001-06-21 Sanofi-Synthelabo Derives de quinazolinedione et phtalimide, leurs preparations et leurs applications en therapeutique
WO2008133155A1 (fr) * 2007-04-19 2008-11-06 Astellas Pharma Inc. Composé hétérocyclique bicyclique
WO2009077680A1 (fr) * 2007-10-03 2009-06-25 Sanofi-Aventis Dérivés de quinazolinedione, leur préparation et leurs applications thérapeutiques

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 2009, Derwent World Patents Index; AN 2009-A77118, XP002554032 *
LOWE J A ET AL: "Structure-Activity Relationship of Quinazolinedione Inhibitors of Calcium-Independant Phosphodiesterase", 1 January 1991, JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, PAGE(S) 624 - 628, ISSN: 0022-2623, XP002483510 *

Also Published As

Publication number Publication date
NZ595768A (en) 2012-12-21
AU2010233594A1 (en) 2011-11-03
UY32556A (es) 2010-11-30
BRPI1014904A2 (pt) 2016-04-19
SG10201401232QA (en) 2014-08-28
AU2010233594B2 (en) 2016-07-07
CN102459244A (zh) 2012-05-16
WO2010116088A2 (fr) 2010-10-14
CN102459244B (zh) 2015-07-08
CL2011002522A1 (es) 2012-02-17
FR2944282B1 (fr) 2013-05-03
FR2944282A1 (fr) 2010-10-15
EA021765B1 (ru) 2015-08-31
CO6440583A2 (es) 2012-05-15
US8722659B2 (en) 2014-05-13
JP5564101B2 (ja) 2014-07-30
KR20120028872A (ko) 2012-03-23
CA2758233A1 (fr) 2010-10-14
EP2417130A2 (fr) 2012-02-15
MX2011010639A (es) 2012-01-19
US20120115846A1 (en) 2012-05-10
IL215609A0 (en) 2011-12-29
ZA201107363B (en) 2012-12-27
JP2012523397A (ja) 2012-10-04
SG175130A1 (en) 2011-11-28
EA201171228A1 (ru) 2012-05-30
MA33255B1 (fr) 2012-05-02
AR076233A1 (es) 2011-05-26
TW201040148A (en) 2010-11-16

Similar Documents

Publication Publication Date Title
WO2010116088A3 (fr) Dérivés de quinazolinedione, leur préparation et leurs diverses applications thérapeutiques
WO2008152099A3 (fr) Aryl/hétarylamides en tant que modulateurs du récepteur ep2
MX2012001974A (es) Compuestos de biarilo y metodos de uso de los mismos.
UA102251C2 (ru) Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
WO2009145456A3 (fr) Dérivés hétérocycliques
WO2007104789A3 (fr) Dérivés d'amyline
MX354144B (es) Metodo, fabricacion y uso de productos medicos que liberan sustancia activa para mantener vasos sanguineos abiertos.
WO2008016643A3 (fr) Entités chimiques, compositions et méthodes
TW200800968A (en) Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
WO2009005677A3 (fr) Composés antiviraux
WO2009005676A3 (fr) Composés antiviraux
WO2008152093A3 (fr) Diaminopyrimidines en tant que modulateurs du récepteur ep2
MX2011013016A (es) Derivados de aminopirrolidinona y usos de los mismos.
WO2008001195A3 (fr) Nouveaux procédés de synthèse d'inhibiteurs de dpp iv
WO2008132234A3 (fr) Composés antagonistes de l'arn pour la modulation de la béta caténine
ZA201007059B (en) Quinoxalinone derivatives as insulin secretion stimulators,methods for obtaining them and use thereof for the treatment of diabetes
ATE554076T1 (de) Sulfoximinsubstituierte chinazolinderivate als immunmodulatoren, ihre herstellung und ihre verwendung als medikamente
WO2009074247A8 (fr) Nouveaux dérivés d'amide d'acide 2-arylthiazole-4-carboxylique, leur préparation et leur utilisation en tant que médicament
WO2011001122A3 (fr) Dérivés de pyrazoles, leur préparation et leur application en thérapeutique
WO2008016666A3 (fr) Entités chimiques, compositions et méthodes
IN2012DN00953A (fr)
MX2009010374A (es) Derivados de tetrahidro-naftalenamina sustituidos con heterociclilo, su preparacion y su uso como medicamentos.
WO2010136035A3 (fr) Composés inédits modulant les récepteurs du calcium et leur utilisation pharmaceutique
IL215103A0 (en) N-[(6-AZA-bicyclo[3.2.1]OCT-5-YL]-ARYL-METHYL]-HETEROBENZAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE OF SAME

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080025349.0

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: DZP2011000680

Country of ref document: DZ

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10723214

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 4124/KOLNP/2011

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 215609

Country of ref document: IL

Ref document number: 11131880

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 2011002522

Country of ref document: CL

Ref document number: 2758233

Country of ref document: CA

Ref document number: 2012504055

Country of ref document: JP

Ref document number: MX/A/2011/010639

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 595768

Country of ref document: NZ

Ref document number: 2010723214

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2010233594

Country of ref document: AU

Date of ref document: 20100407

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20117026561

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 201171228

Country of ref document: EA

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: PI1014904

Country of ref document: BR

ENP Entry into the national phase

Ref document number: PI1014904

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20111010